Simulations Plus Outlines Paths to Win at 2023 Investor Day
- None.
- None.
Demonstrates How Putting Clients First Drives Growth and Fuels Innovation
Reiterates 2024 Guidance
Chief Executive Officer Shawn O’Connor, Chief Financial Officer Will Frederick, and other members of the leadership team will present an in-depth review of the Company’s client-centric business model as well as outline how its new organizational structure better aligns its business with their clients and facilitates future growth. During the event, there will be an opportunity for attendees to ask questions during the Q&A session.
"We look forward to sharing a comprehensive update of our strategic objectives and how putting our clients first drives growth and fuels innovation,” said O’Connor.
“Our paths to win are centered on four key areas: providing unparalleled offerings and a client-centric business model to our clients, continuing to focus on areas that clients find most important, leading the industry in ease-of-use, and building upon our strong relationship-based model.
“Our reorganization reflects the spirit of collaboration that is taking place throughout our organization. Our objective is to operate as ‘one company’ and advance our internal alignment with our clients’ needs as we transition our company from acquisition-based divisions to strategic business units defined by our areas of scientific expertise.
“We have a long history of innovation in biosimulation that is transforming drug development and R&D and a strong financial position to fund our growth. Today, our highly experienced leadership team will demonstrate the rich future for growth opportunities here at Simulations Plus.”
Reiterates Fiscal 2024 Guidance
The Company reiterated previously announced fiscal 2024 guidance which is based upon a status quo outlook compared to fiscal 2023.
-
Revenues are expected to increase in the range of 10
-15% , or$66 $69 million -
Software expected to contribute 55
-60% of revenues and Services expected to contribute 40-45% , reflecting the increased Services revenue from the Immunetrics acquisition. -
Diluted earnings per share is expected to be in the range
$0.66 $0.68 -39% .
The live webcast will begin at 1:00 p.m. Eastern time and conclude at approximately 3:00 p.m. ET. The webcast and presentations can be accessed on the Investor Relations section of the company’s website at https://www.simulations-plus.com/investorscorporate-profile/conference-calls/. Interested parties unable to attend will be able to view and listen to an archived copy of the webcast following the conclusion of the event.
About Simulations Plus, Inc.
Serving clients worldwide for more than 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge artificial intelligence (AI)/machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on LinkedIn | Twitter | YouTube.
Environmental, Social, and Governance (ESG)
We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2022 ESG update.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231114820961/en/
Simulations Plus Investor Relations
Renee Bouche
661-723-7723
renee.bouche@simulations-plus.com
Financial Profiles
Tamara Gonzalez
310-622-8234
slp@finprofiles.com
Source: Simulations Plus, Inc.
FAQ
What is Simulations Plus, Inc. (Nasdaq: SLP) hosting?
Who will be presenting at the event?
What is the fiscal 2024 guidance reiterated by the company?
Where can the webcast and presentations be accessed?
